임상 진단 시장 규모, 점유율, 동향, 예측 : 검사, 제품, 최종사용자, 지역별(2025-2033년)

The global clinical diagnostics market size was valued at USD 86.9 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 156.4 Billion by 2033, exhibiting a CAGR of 6.05% from 2025-2033. North America currently dominates the market in 2024. The increasing number of autoimmune disorders, rising trend of medical tourism, particularly in countries with advanced healthcare systems, and the growing inclination towards personalized medicine and diagnostics are some of the major factors propelling the market.

Clinical diagnostics refer to a branch of medicine that focuses on detecting and identifying diseases and medical conditions. They allow healthcare professionals to accurately diagnose a wide range of illnesses through various tests, procedures, and evaluations. They provide reliable and timely information that aids in medical decision making. They also offer clinicians data that is vital for assessing patient health, planning treatment protocols, and making prognostic evaluations by employing a range of sophisticated methodologies. They play an essential role in healthcare by supporting accurate and early diagnoses, which facilitates preventive care and monitors the effectiveness of treatments.

The increasing number of autoimmune disorders like lupus and rheumatoid arthritis are driving the need for specialized clinical diagnostics to detect these conditions early and manage them effectively around the world. Moreover, the rising trend of medical tourism, particularly in countries with advanced healthcare systems, is catalyzing the demand for a wide range of clinical diagnostic tests. In addition, the growing inclination towards personalized medicine and diagnostics on account of the surging prevalence of chronic and infectious diseases and the increasing aging population, which is more prone to develop these medical conditions, is influencing the market positively. Apart from this, the rising number of specialized diagnostic centers ensure easier access to testing, which is favoring the growth of the market. Furthermore, the growing preference for point of care testing (POCT) that allows healthcare providers to diagnose and monitor patients at the point of care quickly and easily is creating a positive outlook for the market.

Clinical Diagnostics Market Trends/Drivers:

Increase in lifestyle diseases

The prevalence of lifestyle-related diseases like obesity, hypertension, and diabetes is on the upswing, globally. The sedentary lifestyles and poor dietary habits prevalent today contribute significantly to these conditions. Clinical diagnostics play a crucial role in early detection, facilitating preventive measures and tailored treatment plans. Timely diagnosis can often be lifesaving and can reduce the overall burden on healthcare systems. The rise in lifestyle diseases thereby elevates the need for advanced clinical diagnostics to manage and contain these conditions effectively.

Rise in healthcare awareness

The public is becoming more aware about the importance of healthcare and preventative measures, partly due to increased accessibility to information via the internet and public health campaigns. This increased awareness is leading to a higher rate of people seeking regular check-ups and diagnostic tests as part of preventative healthcare. Such proactive health management significantly drives the demand for clinical diagnostics, as individuals seek to understand their health metrics and catch potential issues early.

Growing government initiatives and policies

Governments worldwide are investing heavily in healthcare infrastructure and promoting policies that encourage regular medical screenings. Initiatives, such as subsidized healthcare, public health campaigns targeting early disease detection, and increased funding for medical research have a direct impact on the demand for clinical diagnostics. These programs make diagnostic services more accessible and affordable for the population, thereby driving up utilization rates.

Clinical Diagnostics Industry Segmentation:

Breakup by Test:

• Lipid Panel
• Liver Panel
• Renal Panel
• Complete Blood Count
• Electrolyte Testing
• Infectious Disease Testing
• Others

Lipid panel dominates the market

A liver panel is a group of blood tests that evaluate the function of the liver and check for signs of liver damage or inflammation. The panel can include tests like alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin, among others. These results can aid in diagnosing liver diseases such as hepatitis or cirrhosis, and can also monitor the effects of certain medications on the liver.

The renal panel, also commonly known as a kidney panel, consists of various tests aimed at assessing kidney function. It often includes measurements of elements such as creatinine, blood urea nitrogen (BUN), and electrolytes like sodium, potassium, and chloride. The test is critical for diagnosing kidney diseases and for monitoring individuals who are at risk for kidney complications due to conditions like diabetes or high blood pressure.

Breakup by Product:

• Instruments
• Reagents
• Others

Instruments holds the largest share in the market

Reagents are the chemical substances or compounds used in conjunction with diagnostic instruments to conduct tests. They interact with the samples of blood, urine, or tissue to produce measurable outcomes. Reagents can include antibodies used in immunoassays, chemical indicators, and enzymes. They are typically produced under strict quality control measures to ensure their efficacy and reliability.

Breakup by End User:

• Hospital Laboratory
• Diagnostic Laboratory
• Point-of-care Testing
• Others

Diagnostic laboratory dominates the market

Point-of-care testing (POCT) refers to diagnostic tests that are conducted at or near the site where care is provided, usually by non-laboratory personnel. These tests are often simpler and quicker, designed to provide immediate results that can be acted upon without delay. Examples include glucose monitoring for diabetes patients and rapid strep tests in a primary care setting. POCT is invaluable in situations that require quick decision-making and immediate treatment.

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest clinical diagnostics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The increasing awareness about the benefits of clinical diagnostics among the masses represents one of the primary factors bolstering the market growth in the North American region. Moreover, the rising adoption of automation in medical testing is contributing to the market growth in the region. Besides this, the growing utilization of mobile health (m-health) applications is influencing the market positively.

Competitive Landscape:

The leading companies are integrating artificial intelligence (AI), machine learning (ML), and the internet of things (IoT) to interpret complex data sets, including medical images like X-rays and MRIs that can identify patterns and anomalies that can be missed by human eyes, thereby increasing the accuracy of diagnoses. They are also using genomic sequencing technologies like next-generation sequencing (NGS) that enable rapid and accurate identification of genetic markers for various diseases, which allows for personalized treatment plans that are more targeted and effective. Moreover, key players are utilizing liquid biopsy that allows for the detection of cancer cells or DNA fragments in the blood, which offers a less invasive alternative to traditional tissue biopsies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Becton Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Qiagen N.V.
• Quest Diagnostics Incorporated
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc

Key Questions Answered in This Report

• 1.What is clinical diagnostics?
• 2.How big is the clinical diagnostics market?
• 3.What is the expected growth rate of the global clinical diagnostics market during 2025-2033?
• 4.What are the key factors driving the global clinical diagnostics market?
• 5.What is the leading segment of the global clinical diagnostics market based on test?
• 6.What is the leading segment of the global clinical diagnostics market based on product?
• 7.What is the leading segment of the global clinical diagnostics market based on end user?
• 8.What are the key regions in the global clinical diagnostics market?
• 9.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Clinical Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Test

• 6.1 Lipid Panel
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Liver Panel
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Renal Panel
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Complete Blood Count
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Electrolyte Testing
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Infectious Disease Testing
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Product

• 7.1 Instruments
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Reagents
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospital Laboratory
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostic Laboratory
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Point-of-care Testing
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Becton Dickinson and Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 bioMerieux SA
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Bio-Rad Laboratories Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Danaher Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 F. Hoffmann-La Roche AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 SWOT Analysis
  • 14.3.7 Qiagen N.V.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Quest Diagnostics Incorporated
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Siemens AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Sysmex Corporation
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Thermo Fisher Scientific Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis